Targeted therapies have allowed for an individualized treatment approach in non-small-cell
lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy …

Lung cancer, a leading cause of cancer-related mortality, has a low rate of early diagnosis
and a poor prognosis for advanced stages. Recent advances in further mastery of the …

The development of targeted therapies has improved survival rates for patients with
advanced non-small cell lung cancer (NSCLC). However, tissue biopsy is unfeasible or …

Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or
any other body fluid. This concept is particularly relevant in lung cancer as the tumour is …

Abstract Purpose of Review Liquid biopsies have potential as tools for diagnosis, prognosis,
and prediction of response to therapy. Herein, we will extensively review four liquid …

Simple Summary During the development and progression of lung tumors, processes such
as necrosis and vascular invasion shed tumor cells or cellular components into various fluid …

Precision medicine has revolutionized the therapeutic management of cancer patients with a
major impact on non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma …

Non-small cell lung cancer is one leading cause of death worldwide, and patients would
greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged …

Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …

Lung cancer is the leading cause of cancer mortality. A substantial progress in the
understanding of lung cancer biology has resulted in several promising targeted therapies …